A5113209789- Breastfeeding Practices and Influences
- Bariatric Surgery and Outcomes
- Fibroblast Growth Factor Research
- Adipose Tissue and Metabolism
- Diabetes Treatment and Management
- Neuropeptides and Animal Physiology
- Receptor Mechanisms and Signaling
AstraZeneca (United Kingdom)
2024-2025
Abstract Several peptide dual agonists of the human glucagon receptor (GCGR) and glucagon-like peptide-1 (GLP-1R) are in development for treatment type 2 diabetes, obesity their associated complications. Candidates must have high potency at both receptors, but it is unclear whether limited experimental data available can be used to train models that accurately predict activity receptors new variants. Here we use sequence labelled with vitro GCGR GLP-1R several models, including a deep...
Several groups of neurons in the NTS suppress food intake, including Prlh-expressing (NTSPrlh cells). Not only does artificial activation NTSPrlh cells decrease feeding, but also expression Prlh (which encodes neuropeptide PrRP) and neurotransmission by contributes to restraint intake body weight, especially animals fed a high fat diet (HFD). We set out determine roles for putative PrRP receptors response exogenous PrRP-related peptides. used lacking GPR10 and/or GPR74 (encoded Prlhr Npffr2,...
Bariatric surgery is effective for the treatment and remission of obesity type 2 diabetes, but pharmacological approaches which exert similar metabolic adaptations are needed to avoid post-surgical complications. Here we show how G49, an oxyntomodulin (OXM) analog dual glucagon/glucagon-like peptide-1 receptor (GCGR/GLP-1R) agonist, triggers inter-organ crosstalk between adipose tissue, pancreas, liver initiated by a rapid release free fatty acids (FFAs) white tissue (WAT) in GCGR-dependent...